Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis ; volume:20 ; number:5 ; day:10 ; month:7 ; year:2023 ; pages:1284-1293 ; date:9.2023
Neurotherapeutics ; 20, Heft 5 (10.7.2023), 1284-1293, 9.2023
- Creator
-
Lambru, Giorgio
Caponnetto, Valeria
Hill, Bethany
Ratti, Susanna
Sacco, Simona
Murphy, Madeleine
Briscoe, Jessica
Andreou, Anna P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13311-023-01394-0
- URN
-
urn:nbn:de:101:1-2023111511533193446457
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lambru, Giorgio
- Caponnetto, Valeria
- Hill, Bethany
- Ratti, Susanna
- Sacco, Simona
- Murphy, Madeleine
- Briscoe, Jessica
- Andreou, Anna P.
- SpringerLink (Online service)
Other Objects (12)
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
CGRP and migraine: neurogenic inflammation revisited
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Anti-CGRP in cluster headache therapy: a response
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
CGRP-targeted medication in chronic migraine - systematic review
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
CGRP and migraine: neurogenic inflammation revisited
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Anti-CGRP in cluster headache therapy: a response
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
CGRP-targeted medication in chronic migraine - systematic review
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
The Anti-Calcitonin Gene-Related Peptide (Anti-CGRP) Antibody Fremanezumab Reduces Trigeminal Neurons Immunoreactive to CGRP and CGRP Receptor Components in Rats
CGRP and migraine: neurogenic inflammation revisited
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
Anti-CGRP in cluster headache therapy: a response
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
CGRP-targeted medication in chronic migraine - systematic review
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?